Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT06645639
Active, not recruiting Observational

Implementation of P-INPAC

NCT06645639 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2023-09-04
Last updated
2026-06-24

Condition(s) studied

Malnutrition, ChildNutrition Poor

Investigational drug(s) / intervention(s)

Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC)

Pediatric Integrated Nutrition Pathway for Acute Care Pathway (P-INPAC): The pediatric working group of Canadian Malnutrition Task Force has developed an evidence-informed algorithm named the Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC). The P-INPAC outlines a process to improve nutrition care by: 1. implementing nutrition screening at point-of-admission 2. introducing standard care measures to prevent the development of malnutrition in children admitted with normal nutrition status, including standardizing the process of monitoring food intake early and systematically to identify when standard care measures are not sufficient 3. ensuring the moderately and severely malnourished patients receive timely specialized care in the form of a comprehensive assessment and treatment; and 4. ensuring moderately and severely malnourished patients receive adequate post discharge follow-up and nutrition care. In this pilot study, we will be implementing the first two steps of P-INPAC only (screening and assessment).

Study summary

The framework for Pediatric Integrated Nutrition Pathway for Acute Care (P-INPAC) was developed by the Canadian Malnutrition Task Force (CMTF); however, it has not been implemented in a research setting. The framework by CMTF for Integrated Nutrition Pathway for Acute Care (INPAC) in adults was also implemented in the "More-2-Eat" project which led to development of best practices in nutritional culture of the hospitals. Therefore, we intend to undertake this feasibility project at 3-sites to train staff and evaluate the implementation of P-INPAC components as part of routine healthcare procedure.

Eligibility

Sex
ALL
Min age
30 Days
Max age
18 Years
Healthy volunteers
Accepted
Phase 1 and Phase 3 - Audited patient group inclusion Criteria: 1. ≥ 30 days of age and less than18 years of age on day of assessment 2. Anticipated Length of hospital stay ≥24 hours from day of assessment Phase 1 \& Phase 3 Detailed patient group inclusion Criteria: 1. Admitted to either a general medical or surgical ward 2. ≥ 30 days of age and less than 18 years of age on day of assessment 3. Anticipated Length of stay ≥ 24 hours from day of assessment 4. Speak English (or French at Quebec site) or have a family proxy available at the meal to provide information if first language of patient is not English (or French at Quebec site) 5. Patient/ caregiver provides written consent to participate Exclusion Criteria: a. Patients with eating disorder, somatization disorders, ARFID, FORM 1 etc. where the study interaction might interfere with the messaging or therapeutic plan as set out by the responsible team. Phase 1 and 3 for Health Care Providers inclusion criteria: 1. Implied consent to participate by completing the KAP questionnaire 2. Providing clinical service for the select ward

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
McMaster Children's Hospital Hamilton Ontario
The Hospital for Sick Children Toronto Ontario
Ste-Justine UHC Montreal Quebec

More The Hospital for Sick Children trials in Canada

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06645639 on ClinicalTrials.gov ↗ ← All trials in Canada